filmov
tv
TARGETING ALK POSITIVE LUNG CANCER: BRUCE’S STORY

Показать описание
Last year, 234,000 Americans were expected to be diagnosed with lung cancer. Of those, about 15 percent occurred in people with no risk factors. See how a cutting-edge targeted therapy is helping some patients survive.
Alecensa: Targeted Therapy for ALK-Positive Lung Cancer
ALK-TKIs: targeted therapies for ALK-positive NSCLC
How do ALK-inhibitors work in ALK-positive lung cancer?
2023 Best of Lung: Targeted Therapies in Lung Cancer
A Case of ALK-Rearranged Non–Small Cell Lung Cancer
Targeting ALK rearrangements in non-small cell lung cancer
Targeted TKIs Used for Treatment of ALK-Positive NSCLC
Sequencing Strategies for ALK-Targeted Therapy
Exploring Treatment Options for Patients with ALK-Mutated Lung Cancer
The Evolution of ALK/ROS1-Targeted Therapy in NSCLC
ALK-Positive NSCLC
How do doctors treat ALK-rearranged lung cancer?
Updates and unmet needs in ALK-mutated lung cancer
ALK-Positive NSCLC: ALEX Trial
Progress in the treatment of ALK-positive non-small cell lung cancer
Treatment Access for ALK+ Lung Cancer Patients
ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice Shaw
Targeted Therapy for ALK+ NSCLC
Targeted Therapy Resistance Mechanisms in ALK+ NSCLC
Case Study: MET and ALK Targeted Therapies in NSCLC
GRACE Targeted Therapies Lung Cancer 2021 - ALK Therapies-Which One Comes First, How Do We Sequence?
Dr. Christina Baik on Alectinib in Patients With ALK-Lung Cancer
Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer
Dr. Mott Discusses Targeted Therapy for ALK+ NSCLC
Комментарии